<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> is characterized by a progressive resistance of peripheral tissues to insulin </plain></SENT>
<SENT sid="1" pm="."><plain>Recent data have established the <z:chebi fb="23" ids="18059">lipid</z:chebi> phosphatase SH2 domain-containing <z:chebi fb="1" ids="24848">inositol</z:chebi> phosphatase 2 (SHIP2) as a critical negative regulator of insulin signal transduction </plain></SENT>
<SENT sid="2" pm="."><plain>Mutations in the SHIP2 gene are associated with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Here, we used hyperglycemic and hyperinsulinemic KKA(y) mice to gain insight into the signaling events and metabolic changes triggered by SHIP2 inhibition in vivo </plain></SENT>
<SENT sid="4" pm="."><plain>Liver-specific expression of a dominant-negative SHIP2 mutant in KKA(y) mice increased basal and insulin-stimulated Akt phosphorylation </plain></SENT>
<SENT sid="5" pm="."><plain>Protein levels of <z:chebi fb="105" ids="17234">glucose</z:chebi>-6-phosphatase and <z:chebi fb="0" ids="18021">phosphoenolpyruvate</z:chebi> carboxykinase were significantly reduced, and consequently the liver produced less <z:chebi fb="105" ids="17234">glucose</z:chebi> through gluconeogenesis </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore, SHIP2 inhibition improved hepatic <z:chebi fb="15" ids="28087">glycogen</z:chebi> metabolism by modulating the phosphorylation states of <z:chebi fb="15" ids="28087">glycogen</z:chebi> phosphorylase and <z:chebi fb="15" ids="28087">glycogen</z:chebi> synthase, which ultimately <z:hpo ids='HP_0006568'>increased hepatic glycogen content</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Enhanced glucokinase and reduced <z:chebi fb="1" ids="15361">pyruvate</z:chebi> dehydrogenase kinase 4 expression, together with <z:hpo ids='HP_0002155'>increased plasma triglycerides</z:hpo>, indicate improved glycolysis </plain></SENT>
<SENT sid="8" pm="."><plain>As a consequence of the insulin-mimetic effects on <z:chebi fb="15" ids="28087">glycogen</z:chebi> metabolism, gluconeogenesis, and glycolysis, the liver-specific inhibition of SHIP2 <z:mp ids='MP_0005292'>improved glucose tolerance</z:mp> and markedly reduced prandial blood <z:chebi fb="105" ids="17234">glucose</z:chebi> levels in KKA(y) mice </plain></SENT>
<SENT sid="9" pm="."><plain>These results support the attractiveness of a specific inhibition of SHIP2 for the prevention and/or treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>